SMA Peg denied for missing prior authorization by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

A prior authorization (PA) denial for a pegylated SMA therapy from Anthem typically means either that authorization was not obtained before dispensing, or that a PA was submitted and denied because the clinical documentation did not satisfy Anthem's coverage criteria. PA denials are among the most commonly and successfully appealed denial types — the clinical case rarely changes between denial and appeal; what changes is the completeness and organization of the documentation.

## Your Federal Appeal Rights

Under ACA §2719 you have the right to a full internal appeal and then independent external review through an IRO. ERISA §503 provides the full-and-fair-review standard for employer plans. The external review window is generally four months from the denial date. If SMA progression is occurring and delay in therapy constitutes serious clinical risk, request expedited review — the prescribing physician's certification is the key document for that request. Some states also allow concurrent external review at the time of Level 1 appeal for serious conditions; check your state's insurance regulations.

## Concrete Appeal Steps

1. Obtain the denial letter and determine whether the denial is (a) PA not submitted, (b) PA submitted but documentation insufficient, or (c) PA submitted and denied on clinical grounds. 2. Request Anthem's published PA criteria for the specific drug — the plan must disclose these. 3. Audit the original PA submission against those criteria and identify every documentation gap. 4. File a Level 1 internal appeal (or a retroactive PA request if the drug was urgently dispensed) with a complete, criteria-mapped clinical package. 5. Escalate to external review if Level 1 is upheld; request expedited review if clinical urgency applies.

## Documentation to Gather

• Diagnosis confirmation: Genetic test confirming SMA type and relevant molecular characteristics; specialist notes establishing the clinical indication and patient profile against the FDA-approved label.
• Prior treatment history: Chronological record of all prior SMA therapies with initiation dates, durations, and documented responses or failure reasons — directly addressing any step-therapy requirements embedded in Anthem's PA criteria.
• Clinical severity: Functional status assessments, pulmonary data, nutritional status, and disease trajectory from the chart — described qualitatively as supporting the prescribing physician's clinical judgment.
• Prescriber medical-necessity letter: A detailed letter from the treating neurologist explaining how the patient meets the FDA-approved indication, referencing the applicable guideline organization (e.g., AAN or relevant neuromuscular specialty guidance), and responding point-by-point to each of Anthem's PA criteria.
• Urgency certification (if applicable): Physician statement explaining why delay in therapy would seriously jeopardize health, to support expedited review.

## Criteria-Mapping Structure

Create a table with three columns: Anthem's PA criterion (verbatim), the chart evidence or clinical fact satisfying it, and the source document with date. Submit this table as the first substantive page of the appeal package, before the narrative letter. Reviewers processing high volumes of appeals respond to organized, directly responsive submissions — this format minimizes the chance of a criterion being overlooked.